B+
Bull case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
ABCL
AbCellera BiologicsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The earnings update materially improved the near-term thesis versus the prior baseline because ABCL635 showed clean early safety, target engagement, and a monthly-dosing profile, while liquidity remained substantial enough to fund the next clinical milestones. That supports a cautious positive revision to the evidence base even though the stock is still waiting on Phase 2 efficacy.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
ABCL635 still lacks the Phase 2 efficacy data that would more fully validate the pipeline pivot; disappointing Q3 2026 results would likely pressure the shares.
Momentum
99
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.20 · Bull $7.50 · Bear $3.00Analysis 2026-05-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $17.13
Why
Momentum99 · Δ7d -0.1
Value41 · Δ7d 0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • ABCL635 still lacks the Phase 2 efficacy data that would more fully validate the pipeline pivot; disappointing Q3 2026 results would likely pressure the shares.
- • Partner-led programs with downstream participation declined to 40 from 44 at December 31, 2025, which could reinforce concern that platform optionality is narrowing as the story becomes more dependent on internally led assets. [#8-K-2026-05-11]
- • The strongest bear point is that the May 11 update was not the decisive efficacy event: the new data were interim Phase 1 biomarker and tolerability results, partner-led progressing programs fell to 40 from 44 quarter-end to quarter-end, operating cash use remained meaningful, and the stock still needs a successful Q3 2026 readout to justify a durable rerating.
Catalyst clock
2026-05-11
ABCL635 interim Phase 1 data de-risked the program but left the main efficacy test ahead
Lead driver: Value · See fundamentals
Momentum
99
9% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.4
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 99.5 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-14. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.20
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.63B
Beta
0.80
Shares Out
324.05M
P/E (TTM) · Derived
-22.9
P/S (TTM)
29.07
P/FCF (TTM) · Derived
-28.24
Rev YoY
-76.3%
EPS YoY
+56.0%
Gross Margin
+50.7%
Op Margin
-340.3%
Net Debt
-$417.11M
Current Ratio
12.77
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data